- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04481594
A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects
A Randomized, Double-Blind, Placebo Controlled, Sequential Parallel Group, Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HPN-01
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study aims to obtain safety, tolerability, pharmacokinetic and pharmacodynamic data when HPN-01 is orally administered as single doses and as multiple doses to healthy subjects.
The study will be conducted in 2 parts: a single ascending dose (SAD) phase (Part 1) and a multiple ascending dose (MAD) phase (Part 2). One cohort of Part 1 will receive HPN-01 after a standard high fat/high calorie breakfast (the fed condition) to investigate the effect of food on the pharmacokinetics of HPN-01.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Michelle Pluviose, MS
- Phone Number: 201-416-7763
- Email: mpluviose@frontagelab.com
Study Contact Backup
- Name: Annie Li, MD
- Phone Number: 201-416-7770
- Email: ali@frontagelab.com
Study Locations
-
-
New Jersey
-
Secaucus, New Jersey, United States, 07094
- Recruiting
- Frontage Clinical Services, Inc
-
Contact:
- Michelle Pluviose, MS
- Phone Number: 201-416-7763
- Email: mpluviose@frontagelab.com
-
Contact:
- Annie Li, MD
- Phone Number: 2014167770
- Email: ali@frontagelab.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Are capable of giving informed consent and complying with study procedures;
- Are between the ages of 18 and 55 years, inclusive;
Female subjects have a negative pregnancy test result at screening and admission to the study site, and meet one of the following criteria:
- Using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives) [e.g., hormonal contraceptives (oral, patch, injectable or vaginal ring), implantable device (implantable rod or intrauterine device), or a double barrier (e.g., diaphragm, cervical cap, oral, patch or vaginal hormonal contraceptive, condom, spermicide, or sponge)]
Surgically sterile for at least 3 months prior to screening by one of the following means:
- Bilateral tubal ligation
- Bilateral salpingectomy (with or without oophorectomy)
- Surgical hysterectomy
- Bilateral oophorectomy (with or without hysterectomy)
Postmenopausal, defined as the following:
- Last menstrual period greater than 12 months prior to screening
- Postmenopausal status confirmed by serum FSH and estradiol levels at screening;
- Considered healthy by the Investigator, based on subject's reported medical history, full physical examination, clinical laboratory tests, 12-lead ECG, and vital signs;
- Normal renal function (eGFR > 90 ml/min/1.75 m2) as determined by Investigator following review of clinical laboratory test results;
- Non-smoker and has not been exposed to any products containing nicotine in the last 6 months;
- Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg;
- Willing and able to adhere to study restrictions and to be confined at the clinical research center;
- Male subjects must agree to utilize a highly effective method of contraception (condom plus spermicide) during heterosexual intercourse from clinic admission until 12 weeks following the end of study visit;
- Male subjects with female partners of child-bearing potential must agree to use condoms for the duration of the study and until 12 weeks after dosing with the study drug and must refrain from donating sperm for this same period.
Exclusion Criteria:
- Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator;
- Known or suspected malignancy;
- Reported history of pancreatitis or gall stones;
- Reported history of unexplained syncope, symptomatic hypotension or hypoglycemia;
- Family history of long QTc syndrome;
- History of chronic diarrhea, malabsorption, unexplained weight loss, food allergies or intolerance;
- Poor venous access;
- Positive blood screen for human immunodeficiency virus (HIV), hepatitis B core (IgG and IgM) and surface antigen (HBsAg), Hepatitis A antibody (IgM), hepatitis C antibody (IgG), or hepatitis E (IgG and IgM) at Screening;
- Donated or lost >500 mL of blood in the previous 3 months prior to screening;
- Taken an investigational drug or participated in a clinical trial within 3 months (or 5 half-lives) prior to first dose of study drug, whichever is longer;
- Taken any prescription medications (with the exception of hormonal contraceptive) within 14 days or 5 half-lives (whichever is longer) of the first dose of study drug;
- Hospital admission or major surgery within 6 months prior to screening;
- A history of prescription drug abuse, or illicit drug use within 9 months prior to screening;
- A history of alcohol abuse according to medical history (≥ 2 drinks per day for male and ≥ 1 drink per day for female) within 9 months prior to screening;
- A positive screen for alcohol, drugs of abuse at screening or admission;
- An unwillingness or inability to comply with food and beverage restrictions during study participation;
- Use of over-the-counter (OTC) medication within 7 days, and/or herbal medications (including St John's Wort, herbal teas, garlic extracts) within 7 days prior to first dose of study drug (Note: Use of acetaminophen at < 2 g/day is permitted until 24 hours prior to dosing);
- Any condition or finding that in the Investigators opinion would put the subject or study conduct at risk if the subject were to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HPN-01
Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01. One cohort of Part 1 will receive HPN-01 after a standard high fat/high calorie breakfast (the fed condition) to investigate the effect of food on the pharmacokinetics of HPN-01. Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 once daily for a consecutive 14 days. |
25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 capsules
|
PLACEBO_COMPARATOR: Placebo
Part 1: Including 6 dose cohorts (25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg). Each dose cohort will receive a single dose of HPN-01 placebo. Part 2: Including 3 dose cohorts (50 mg, 100 mg and 200 mg). Each dose cohort will receive HPN-01 placebo once daily for a consecutive 14 days. |
25 mg, 50 mg, 100 mg, 150 mg, 200 mg and 300 mg HPN-01 placebo capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Single-dose PK Parameter
Time Frame: Up to 72 hours postdose
|
Cmax of HPN-01
|
Up to 72 hours postdose
|
Single-dose PK Parameter
Time Frame: Up to 72 hours postdose
|
AUClast of HPN-01
|
Up to 72 hours postdose
|
Single-dose PK Parameter
Time Frame: Up to 72 hours postdose
|
AUCinf of HPN-01
|
Up to 72 hours postdose
|
Multiple-dose PK Parameters
Time Frame: Up to 24 hours postdose
|
Cmax of HPN-01
|
Up to 24 hours postdose
|
Multiple-dose PK Parameters
Time Frame: Up to 24 hours postdose
|
Ctau of HPN-01
|
Up to 24 hours postdose
|
Multiple-dose PK Parameters
Time Frame: Up to 24 hours postdose
|
AUCtau of HPN-01
|
Up to 24 hours postdose
|
Incidence of Adverse Events
Time Frame: Up to 15 days plus 6 days
|
Up to 15 days plus 6 days
|
|
Proportion of Participants with 12-lead ECG Abnormalities
Time Frame: Up to 15 days plus 6 days
|
Up to 15 days plus 6 days
|
|
Proportion of Participants with Clinical Laboratory Abnormalities
Time Frame: Up to 15 days plus 6 days
|
Up to 15 days plus 6 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measurement of PD Biomarker Level of Fibroblast Growth Factor 19 (FGF19) Following Oral Single and Multiple Ascending Dose Administration
Time Frame: Up to 24 hours postdose
|
Up to 24 hours postdose
|
Measurement of PD Biomarker Level of C4 Following Oral Single and Multiple Ascending Dose Administration
Time Frame: Up to 24 hours postdose
|
Up to 24 hours postdose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HPN-01-US-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Alcoholic Steatohepatitis (NASH)
-
Corcept TherapeuticsRecruitingNon-alcoholic Steatohepatitis (NASH)United States
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis (NASH)Belgium, Germany, Taiwan, Austria, United States, Spain, Korea, Republic of, Argentina, Australia, Italy, Japan, Singapore, Netherlands, Slovakia, France, Canada, India
-
Immuron Ltd.CompletedNon-alcoholic Steatohepatitis (NASH)United States, Australia, Israel
-
EccogeneRecruiting
-
Guangdong Raynovent Biotech Co., LtdCompletedNon-Alcoholic Steatohepatitis (NASH)China
-
Novartis PharmaceuticalsTerminatedNon-alcoholic Steatohepatitis NASHUnited Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
-
Hoffmann-La RocheCompletedNon-Alcoholic Steatohepatitis (NASH)France
-
University of ZurichCompletedNon-alcoholic Steatohepatitis (NASH)Switzerland
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingNon-Alcoholic Steatohepatitis (NASH)China
-
AstraZenecaActive, not recruitingNon-alcoholic Steatohepatitis (NASH)United States
Clinical Trials on HPN-01
-
Horizon Pharma Ireland, Ltd., Dublin IrelandUcyclyd Pharma, Inc.CompletedHepatic Encephalopathy | Urea Cycle DisordersUkraine
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedHepatic Encephalopathy | CirrhosisUnited States
-
Livzon Pharmaceutical Group Inc.Active, not recruiting
-
Zucara Therapeutics Inc.RecruitingType 1 Diabetes Mellitus With HypoglycemiaUnited States, Canada
-
Ixchelsis LimitedCompletedPremature EjaculationUnited States
-
Shanghai Hongyitang Biopharmaceutical Technology...Completed
-
Enterin Inc.TerminatedParkinson Disease | ConstipationUnited States
-
Zhongmou TherapeuticsRecruitingX-linked RetinoschisisChina
-
BioPharmX, Inc.CompletedAcne VulgarisUnited States
-
Enterin Inc.CompletedParkinson Disease | ConstipationUnited States